Maurizio Gallieni
Overview
Explore the profile of Maurizio Gallieni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
266
Citations
2755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cossettini A, Re Sarto G, Aghi A, Gallieni M, Cosmai L, Tripepi G, et al.
G Ital Nefrol
. 2024 Nov;
41(Suppl 83).
PMID: 39503226
Chronic Kidney Disease (CKD) provokes biochemical and systemic alterations, causing bone fragility with an increase in bone fracture risk, extraskeletal calcifications, increased morbidity, and cardiovascular mortality. The complex pathophysiological mechanism...
2.
Borrelli S, Garofalo C, Reboldi G, Coppola A, Chiodini P, Simeoni M, et al.
Clin Kidney J
. 2024 Nov;
17(11):sfae316.
PMID: 39502370
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) lower ambulatory blood pressure (ABP) in patients with type 2 diabetes mellitus; whether the same holds true in diabetic kidney disease (DKD) is unknown....
3.
Fusaro M, Aghi A, Marino C, Mallamaci F, Plebani M, Zaninotto M, et al.
J Clin Med
. 2024 Oct;
13(19).
PMID: 39407947
Chronic kidney disease and mineral bone disorders (CKD-MBD) are frequently associated with an increased risk of both vascular calcifications (VCs) and bone fractures (BFs). The complex pathogenesis of VCs and...
4.
Pirovano M, Ganini C, Gallieni M, Porta C, Cosmai L
J Nephrol
. 2024 Oct;
PMID: 39404957
The incidence of tumors increases significantly in individuals with chronic kidney disease (CKD), particularly among those undergoing dialysis. This dialysis-associated condition not only impacts therapy but also influences the prognosis...
5.
Plebani M, Zaninotto M, Giannini S, Sella S, Fusaro M, Tripepi G, et al.
Diagnosis (Berl)
. 2024 Sep;
12(1):35-44.
PMID: 39295160
Over the last decades, in addition to the improvement of pathophysiological knowledge regarding the role and mechanisms of action of vitamin D, there has been a progressive advancement in analytical...
6.
Re Sarto G, Alfieri C, Cosmai L, Brigati E, Campise M, Regalia A, et al.
Transpl Int
. 2024 Sep;
37:13220.
PMID: 39228659
We describe the epidemiology of cancer after kidney transplantation (KTx), investigating its risk factors and impact on therapeutic management and survival in KTx recipients (KTRs). The association between modification of...
7.
Gronda E, Gallieni M, Pacileo G, Capasso G, Wei L, Trepiccione F, et al.
Kidney Blood Press Res
. 2024 Aug;
49(1):852-862.
PMID: 39197425
Introduction: Peritoneal ultrafiltration (PUF) has been proposed as an additional therapeutic option for refractory congestive heart failure (RCHF) patients. Despite promising observational studies and/or case report results, limited clinical trial...
8.
Lomonte C, Ibeas J, Kitrou P, Giusto A, Baratto M, Bocchibianchi V, et al.
J Vasc Access
. 2024 Aug;
:11297298241265163.
PMID: 39097789
The Renal Expert in Vascular Access (REVAC) is one of the four modules of the Nephrology Partnership for Advancing Technology in Healthcare (N-PATH) project, the first European-wide advanced training course...
9.
Mitacchione G, Schiavone M, Gasperetti A, Tripepi G, Cerini M, Montemerlo E, et al.
Heart Rhythm
. 2024 Jul;
22(2):325-331.
PMID: 39029882
Background: Limited data are available on leadless pacemaker (LPM) outcomes according to different stages of chronic kidney disease (CKD). Objective: The purpose of this study was to investigate differences in...
10.
Tucci M, Cosmai L, Pirovano M, Campisi I, Re S, Porta C, et al.
Cancer Treat Rev
. 2024 Mar;
125:102692.
PMID: 38492515
We are witnessing a revolution in the treatment of metastatic renal cell carcinoma (mRCC). Indeed, several immune-based combinations (ICI [immune checkpoint inhibitor] + ICI, or ICI + antiangiogenic agents) have...